ClinicalTrials.gg

Program

JAK2 Inhibitor TQ05105

Also written as “TQ05105 tablets”, “TQ05105” and “TQ05105 Tablets”.

In Sino Biopharmaceutical’s pipeline, JAK/ROCK抑制剂. Its studies are mostly in Primary Myelofibrosis · Bronchiolitis Obliterans Syndrome · Myeloproliferative Disorders · Lymphoma, Follicular · Lymphohistiocytosis, Hemophagocytic, led by Sino Biopharmaceutical.

Furthest: phase 2, since Jun 21, 202116 company-led studies, 7 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical167 open or runningphase 2since Jun 21, 2021Mar 26, 2020Dec 2026phase 1 · NCT07708272
  • Named in Sino Biopharmaceutical’s own pipeline as TQ05105, phase 4, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Mar 26, 2020.

  1. Apr 7, 2020Phase 1 study in Myeloproliferative DisordersNCT04339400 · 79 enrolled · China
  2. Jun 21, 20212 phase 2 studiesNCT04944043, NCT04941404
  3. Aug 23, 2021Phase 2 study in Lymphoma, FollicularNCT05020652 · 107 enrolled · China
  4. Jul 7, 2023Phase 1 study in Primary MyelofibrosisNCT05982106 · 16 enrolled · China
  5. Aug 30, 2023Phase 1 study in Primary MyelofibrosisNCT06024915 · 40 enrolled · China
  6. Nov 2, 2023Phase 2 study in Primary MyelofibrosisNCT06122831 · 92 planned · China
  7. Mar 4, 2024Phase 2 study in Bronchiolitis Obliterans SyndromeNCT06300320 · 65 planned · China
  8. Apr 25, 2024Phase 1 study in Primary MyelofibrosisNCT06388759 · 9 enrolled · China
  9. Sep 13, 2024Phase 1 study in Primary MyelofibrosisNCT06598956 · 32 enrolled · China
  10. Dec 8, 2025Phase 1 study in Mass Balance of [14C] TQ05105 in Healthy Chinese SubjectsNCT07293390 · 6 enrolled · China
  11. Mar 14, 2026Phase 1 study in Primary MyelofibrosisNCT07480824 · 24 planned · China
  12. Apr 17, 2026Phase 2 study in Primary MyelofibrosisNCT07551427 · 51 planned · China
  13. May 20, 2026Phase 1 study in Primary MyelofibrosisNCT07608666 · 17 enrolled · China
  14. Jul 13, 2026Phase 1 study in Primary MyelofibrosisNCT07708272 · 60 enrolled · China

Ahead

  1. Dec 2026Primary completion: phase 1 study in Primary MyelofibrosisNCT07708272
  2. Dec 2026Primary completion: phase 1 study in Primary MyelofibrosisNCT07608666
  3. Dec 2026Primary completion: phase 2 study in Primary MyelofibrosisNCT06122831
  4. Nov 2027Primary completion: phase 2 study in Bronchiolitis Obliterans SyndromeNCT06300320

TargetBeta

“JAK/ROCK抑制剂”the company's pipeline, read by Claude · source
“An orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2), with potential antineoplastic activity. Upon oral administration, JAK2 inhibitor TQ05105 inhibits JAK2 activity, thereby preventing the activation of the JAK/STAT (signal transducer and activator of transcription) signaling pat…”NCIt, read by Claude
“An orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2), ”NCIt, by rule

Other programs on JAK2

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
baricitinibruleEli Lillyphase 459
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
jaktinibruleSuzhou Zelgen Biopharmaceuticalsphase 331
delgocitinibruleLEO Pharmaphase 321
pacritinibruleSwedish Orphan Biovitrumphase 318
momelotinibruleGlaxoSmithKlinephase 317
flonoltinibruleChengdu Zenitar Biomedical Technologyphase 37
flonoltinib maleateruleChengdu Zenitar Biomedical Technologyphase 22

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07708272Primary Myelofibrosis · China1Active, not recruitingDec 202660
NCT07608666Primary Myelofibrosis · China1Active, not recruitingDec 202617
NCT07551427Primary Myelofibrosis · China2RecruitingJun 202851
NCT07480824Primary Myelofibrosis · China1RecruitingOct 202624
NCT07293390Mass Balance of [14C] TQ05105 in Healthy Chinese Subjects · China1CompletedApr 8, 20246
NCT06598956Primary Myelofibrosis · China1CompletedMar 17, 202532
NCT06388759Primary Myelofibrosis · China1TerminatedAug 12, 20259
NCT06300320Bronchiolitis Obliterans Syndrome · China2RecruitingNov 202765
NCT06122831Primary Myelofibrosis · China2RecruitingDec 202692
NCT06024915Primary Myelofibrosis · China1CompletedJan 29, 202440
NCT05982106Primary Myelofibrosis · China1CompletedJul 28, 202116
NCT05020652Lymphoma, Follicular · China2CompletedOct 15, 2023107
NCT04941404Glucocorticoid-Refractory aGVHD · China2TerminatedJul 10, 202313
NCT04944043Bronchiolitis Obliterans Syndrome · China2Active, not recruitingJun 30, 202345
NCT04339400Myeloproliferative Disorders · China1CompletedMar 17, 202379
NCT04326348Lymphohistiocytosis, Hemophagocytic · China1UNKNOWNJan 202240

How it is read

Names in the registry

  • “TQ05105 tablets”, 6 entries
  • “TQ05105”, 5 entries
  • “TQ05105 Tablets”, 3 entries
  • “TQ05105 Tablets (Rovadicitinib Tablets)”, 1 entry
  • “TQ05105 Tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.